A 15-day high-dose accelerated intermittent theta-burst stimulation protocol delivered 7,200 magnetic pulses daily to specific brain networks in 45 mild Alzheimer's patients. Targeting either the default mode network or fronto-parietal network produced clinically meaningful cognitive improvements, with response rates of 38% and 47% respectively, compared to 0% in the sham group. Benefits persisted at three-month follow-up. This finding represents a potentially significant advance in non-invasive Alzheimer's treatment, as current FDA-approved drugs like aducanumab and lecanemab show modest benefits with substantial side effects and costs. The specific targeting of established brain networks affected in Alzheimer's pathology suggests a mechanistically informed approach. However, the small sample size of 15 patients per group and short follow-up period limit broader conclusions. As a preprint awaiting peer review, these promising results require validation through larger trials and longer-term safety monitoring. The high daily pulse count raises questions about optimal dosing protocols and potential cumulative effects that need systematic investigation before clinical implementation.